Cardiovascular, Hemostasis, and Anti-Inflammatory Benefits

Evidence Review

PANDA Randomized Controlled Trial (2023)

Wu et al.'s trial published in JAMA Network Open [1] is the largest and most rigorously designed clinical trial of PNS to date. Study design highlights:

• Conducted at 67 tertiary hospitals across China, July 2018–June 2020
• 3,072 patients aged 18–75 with confirmed ischemic stroke, NIHSS 4–15 (moderate stroke)
• Intervention: Xuesaitong soft capsules (a licensed PNS formulation approved in China since 1999), added to standard stroke care
• Double-blind, randomized, placebo-controlled, multicenter design

Primary outcome: Modified Rankin Scale score 0–2 (functional independence) at 90 days — 89.0% PNS vs 82.1% placebo (adjusted odds ratio 1.79, 95% CI 1.30–2.47; p < 0.001).

Secondary outcomes: Significant improvements in the PNS group for NIHSS neurological deficit scores at 14 days and 90 days; reduced rates of major disability (mRS 3–5).

Safety: No significant difference in adverse events or serious adverse events between groups. Notably, no increased bleeding risk was observed — an important safety signal for an agent used in stroke patients who may also receive antithrombotics.

Limitation: The study population was Chinese, and the preparation (Xuesaitong) is not widely available outside China. The absolute baseline rates of functional independence reflect a specific trial population; generalizability to Western stroke populations requires caution.

Cardiovascular Overview: Experimental Evidence (2014)

Yang et al.'s comprehensive review [2] catalogued the cardiovascular pharmacology of PNS monomers across experimental systems. Key findings:

• Rb1: Reduces myocardial infarct size in animal models; inhibits cardiomyocyte apoptosis via upregulation of Bcl-2 and downregulation of Bax; reduces arrhythmia incidence after ischemia-reperfusion
• Rg1: Dilates blood vessels through endothelial nitric oxide synthase (eNOS) activation — a mechanism similar to that of pharmaceutical vasodilators; reduces platelet aggregation; inhibits smooth muscle cell proliferation
• R1: Uniquely potent in platelet aggregation inhibition; protective against blood-brain barrier disruption after stroke

The review identified more than 20 published studies demonstrating significant cardioprotective effects in rodent and cell models, with consistent effects across independent research groups. The authors noted the relative scarcity of large human RCTs at the time of publication — a gap that the PANDA trial has since substantially addressed.

Stroke Meta-Analysis (2021)

Wang et al.'s systematic review [3] synthesized evidence from 43 RCTs involving 4,170 participants with acute ischemic stroke. The analysis compared PNS formulations (injections and oral preparations) added to conventional treatment versus conventional treatment alone. Key findings:

• Improved functional independence at 3 months (limited to one small sample study at time of publication, but consistent direction)
• Significant improvement in neurological function scores (NIHSS reduction) across multiple studies
• Improved activities of daily living (Barthel Index)
• No significant increase in adverse events

Heterogeneity and limitations: The pooled analysis included heterogeneous PNS preparations, dosing regimens, and study quality levels. Injection-based studies dominated the sample. Most trials were conducted in China at single centers. Publication bias cannot be excluded in a literature this geographically concentrated.

Anti-Aging Mechanisms (2017)

Luo et al.'s review in Aging and Disease [4] synthesized evidence for PNS across aging hallmarks:

• In C. elegans lifespan models, PNS significantly extended median lifespan, associated with activation of the DAF-16/FOXO transcription factor pathway (a conserved longevity mechanism shared across species including mammals)
• In vascular smooth muscle cell studies, PNS inhibited the p16-cyclin D/CDK-Rb senescence pathway — preventing cells from entering the growth-arrested, pro-inflammatory state characteristic of aging vasculature
• Neuroinflammation studies showed that notoginsenoside R1 specifically suppressed microglial activation (the brain's resident immune cell) — reducing IL-6, TNF-α, and nitric oxide production in lipopolysaccharide-stimulated models; this effect may underlie the cognitive benefits seen in some animal models
• The review identified the capacity to reduce both telomere damage and mitochondrial dysfunction as two age-related mechanisms through which PNS may slow cellular aging, though human data for these specific endpoints remain limited

Inflammation and IBD (2021)

Zhao et al. [5] used both in vitro (RAW 264.7 macrophages) and in vivo (DSS-induced colitis mouse model) systems to characterize PNS's anti-inflammatory mechanism. PNS at 50–400 mg/kg doses:

• Reduced production of TNF-α, IL-6, and MCP-1 in LPS-stimulated macrophages
• Inhibited NF-κB nuclear translocation (the step that triggers inflammatory gene expression)
• Reduced phosphorylation of ERK, JNK, and p38 (the MAPK pathway nodes)
• In the colitis model: improved colon length, reduced inflammatory cell infiltration, lowered myeloperoxidase activity (a marker of neutrophil-mediated tissue damage)

These dual-pathway anti-inflammatory effects explain why PNS demonstrates broad efficacy across different inflammatory conditions — cardiovascular, gastrointestinal, and neurological — as NF-κB and MAPK are master regulators of inflammation across tissue types.

Evidence Strength Summary

Panax notoginseng has an unusually strong evidence base among traditional herbs, anchored by a large, multicenter, placebo-controlled RCT published in a top-tier journal (JAMA Network Open). Cardiovascular protection mechanisms are well characterized in experimental systems, and a consistent pattern of benefit has been replicated across independent Chinese research groups for decades. The main limitations are: most trial evidence comes from China, the specific licensed preparations used in trials may differ from commercially available supplements in the West, and the herb's complex pharmacology means that different preparations (injection vs. oral, different PNS concentrations) may not be interchangeable. Overall confidence: high for acute ischemic stroke (based on PANDA); moderate for general cardiovascular protection; moderate for anti-inflammatory effects; low-moderate for anti-aging applications in humans.